Science

Esranur Aydın: Metastatic IDH2-mutant cholangiocarcinoma treated with venetoclax and decitabine

Esranur Aydın/LinkedIn

Mar 3, 2025, 15:58

Esranur Aydın: Metastatic IDH2-mutant cholangiocarcinoma treated with venetoclax and decitabine

Esranur Aydın, Clinical Cancer Molecular Biologist at Medicana Sağlık Grubu, shared a post on LinkedIn about a paper she co-authored with colleagues published in JCO Precision Oncology:

“The future of oncology isn’t just about discovering new drugs – it’s about making the right treatments accessible to the right patients at the right time.

Our latest publication in JCO PO reports a response in a metastatic IDH2-mutant cholangiocarcinoma patient treated with venetoclax and decitabine – a combination typically reserved for hematologic malignancies. A 15-month durable response, minimal toxicity, and a glimpse of what targeting shared molecular vulnerabilities could mean for solid tumors.

Sounds promising? Yes. A game-changer? Maybe. A cure? No.

Here’s the reality: For many patients, there are no ‘approved’ options left. Off-label use, experimental combinations, and last-resort interventions shape real-world oncology, yet access remains a privilege for many patients. Even when they do receive treatment with intended agents, success rates are far from the miracle headlines we wish for.

This is why we need more than science – we need action.

Broader access to molecular profiling
Smarter trial designs that break organ-based barriers
Global collaboration to close the treatment gap

This case is not just about one patient. It’s about rethinking oncology, one mutation at a time.

With special thanks to Prof. Dr. Mutlu Demiray for his leadership and commitment, and to our dedicated team – with a heartfelt shoutout to Eylul Ozgu, our first author, who made this study possible Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç.”

“Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2-Mutant Cholangiocarcinoma”

Authors: Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Onur Tutar, Mutlu Demiray.

Esranur Aydın: Metastatic IDH2-mutant cholangiocarcinoma treated with venetoclax and decitabine